This topic contains a solution. Click here to go to the answer

Author Question: A patient with Parkinson's disease is taking levodopa/carbidopa (Sinemet) and reports occasional ... (Read 156 times)

stock

  • Hero Member
  • *****
  • Posts: 573
A patient with Parkinson's disease is taking levodopa/carbidopa (Sinemet) and reports occasional periods of loss of drug effect lasting from minutes to several hours.
 
  The nurse questions the patient further and discovers that these episodes occur at different times related to the medication administration. The nurse will contact the provider to discuss:
  a. administering a catechol-O-methyltransferase (COMT) inhibitor, such as entacapone.
  b. adding the DA-releasing agent amantadine to the regimen.
  c. giving a direct-acting dopamine agonist.
  d. shortening the dosing interval of levodopa/carbidopa.

Question 2

A group of nursing students asks a nurse to explain the blood-brain barrier. The nurse would be correct to say that the blood-brain barrier:
 
  a. prevents some potentially toxic substances from crossing into the central nervous system.
  b. causes infants to be less sensitive to CNS drugs and thus require larger doses.
  c. allows only ionized or protein-bound drugs to cross into the central nervous system.
  d. prevents lipid-soluble drugs from entering the central nervous system.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

raenoj

  • Sr. Member
  • ****
  • Posts: 340
Answer to Question 1

ANS: A
This patient is describing abrupt loss of effect, or the off phenomenon, which is treated with entacapone or another COMT inhibitor. Amantadine is used to treat dyskinesias. A direct-acting dopamine agonist is useful for gradual loss of effect, which occurs at the end of the dosing interval as the dose is wearing off. Shortening the dosing interval does not help with abrupt loss of effect.

Answer to Question 2

ANS: A
The blood-brain barrier can prevent some drugs and some toxic substances from entering the CNS. The blood-brain barrier in infants is not fully developed, so infants are more sensitive to CNS drugs and often require lower doses. The blood-brain barrier prevents highly ionized and protein-bound drugs from crossing into the CNS and allows lipid-soluble drugs and those that can cross via specific transport systems to enter.




stock

  • Member
  • Posts: 573
Reply 2 on: Jul 23, 2018
Great answer, keep it coming :)


6ana001

  • Member
  • Posts: 311
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Sildenafil (Viagra®) has two actions that may be of consequence in patients with heart disease. It can lower the blood pressure, and it can interact with nitrates. It should never be used in patients who are taking nitrates.

Did you know?

There are 20 feet of blood vessels in each square inch of human skin.

Did you know?

The people with the highest levels of LDL are Mexican American males and non-Hispanic black females.

Did you know?

Patients who cannot swallow may receive nutrition via a parenteral route—usually, a catheter is inserted through the chest into a large vein going into the heart.

Did you know?

Methicillin-resistant Staphylococcus aureus or MRSA was discovered in 1961 in the United Kingdom. It if often referred to as a superbug. MRSA infections cause more deaths in the United States every year than AIDS.

Methicilli ...

For a complete list of videos, visit our video library